Search Results for "Boehringer Ingelheim Aquires Vectibix"
Original Source: HORIZON DISCOVERY LIMITED
Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. About Horizon Discovery Horizon Discovery is a leading provider of research tools to support the development of personalized medicines. The Company’s proprietary virally-mediated gene-engineering technology, GENESIS™, enables any endogenous gene in a human cell-line to be altered quickly,...
Matching Channels
Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales. With bases in 47 c...
The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...
Connecticut, a state in the north-east corner of the US is a hub for biotechnology companies. There are over 100 high-quality companies with global markets based in Connecticut. In 2004, Connectic...
Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...
The Top 100 Pharmaceutical Companies
The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and 2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...
Matching News
BaroFold and Boehringer Ingelheim announce strategic alliance for protein refolding technology
BaroFold and Boehringer Ingelheim have entered into a non-exclusive technology and commercial license option agreement.Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s Pres...
Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates
Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called m...
Boehringer Ingelheim announces changes to Board of Managing Directors
The Shareholders of Boehringer Ingelheim have appointed Dr Joachim Hasenmaier to Boehringer Ingelheim’s Board of Managing Directors. The 52-year old will take over responsibility for the new Consume...
Boehringer Ingelheim manufacturing under FDA fire again
The US FDA has issued a warning letter to Boehringer Ingelheim citing "significant violations" at its manufacturing plant in Ingelheim am Rhein, Germany. It said APIs and drug products from the plant...
Boehringer Ingelheim acquires FX125L and somatotaxin portfolio rights
Boehringer Ingelheim and Funxional Therapeutics announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin...
Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio
Boehringer Ingelheim and Funxional Therapeutics, have formed an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin p...
Ensemble Therapeutics and Boehringer Ingelheim ink $186 milliion macrocycle drug pact
Ensemble Therapeutics announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against s...
Boehringer Ingelheim completes biosimilar adalimumab trial
Biopharmaceutical specialist Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) has completed its phase I trial for a biosimilar version of adalimumab.
Matching PubMed Articles
Lessons from 54 years of pharmaceutical research.
Regulatory aspects of devices.
A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent...
Efficient Synthesis of a Small Molecule, Nonpeptide Inhibitor of LFA-1.
A three-stage process for the synthesis of LFA-1 inhibitor 1 from amine 4 with an overall yield of 65% is described. The key stage involves a Ph(3)PCl(2)-induced dehydration/cyclization of urea 6 foll...
Direct titanium-mediated conversion of ketones into enamides with ammonia and acetic anhydride.
A one-step conversion of ketones into N-acetyl enamides was developed. The process employs safe and inexpensive reagents, proceeds under mild conditions, and tolerates diverse functional groups. The a...
